Australia Eased Abortion Pill Rules and Pharmacy Stocking Rose 49%
Pharmacy stocking of MS-2 Step in Australia increased 49% in the two years after the Therapeutic Goods Administration eased prescribing and dispensing restrictions in 2023, according to a study published in JAMA Network Open on Thursday.
The La Trobe University-led research found 4,107 pharmacies were stocking the medication by mid-2025, up from 2,228 before the policy change. The number of postcodes with at least one stocking pharmacy rose from 915 to 1,292 over the same period The Guardian. The lead author was Prof Kristina Edvardsson from La Trobe University's School of Nursing and Midwifery.
Coverage gains were largest outside major cities. The share of regional postcodes with a stocking pharmacy increased from 23% to 35%. In remote areas, the proportion of stocking pharmacies rose from 12.5% to 22%.
The 2023 changes removed several regulatory requirements. After the changes, any general practitioner (GP), or family doctor, in Australia could prescribe MS-2 Step. Previously, GPs needed additional training and registration to prescribe it. The requirement for pharmacists to be registered to dispense MS-2 Step was scrapped. Appropriately trained nurse practitioners and endorsed midwives also became eligible prescribers.
Australia's Therapeutic Goods Administration, the national medicines regulator, stated that MS-2 Step can be prescribed by any healthcare practitioner with appropriate qualifications and training Therapeutic Goods Administration. ABC News reported on 10 July 2023 that changes to abortion regulation would take effect the next month in a bid to increase access ABC News.
MS-2 Step comprises mifepristone and misoprostol, two drugs taken together. It can be taken until up to 63 days of gestation, or pregnancy, and is available under Australia's Pharmaceutical Benefits Scheme, the national subsidy that lowers prescription costs. At the time of the study, it was the only abortion pill available in Australia. It is taken for medical abortion, which ends an early pregnancy with medication rather than a procedure.
Access remains uneven. A 2026 study found many Australian women struggled to access early medication abortion because of where they lived, even as more GPs were offering it by 2026 MJA Insight+. In the United States, medication abortion accounted for 54% of abortions, according to data from the Guttmacher Institute.
The broader context here is the difference between authorization and availability. The TGA action lowered the threshold for who could prescribe and dispense. Pharmacy stocking responded quickly at national scale. Like expanded shelf space in stores, the postcode data indicate the response extended beyond metropolitan dispensing networks, with regional and remote gains outpacing the national average in percentage-point terms.
Looking at what this means for service delivery, stocking is a necessary but partial measure. It tracks where a prescription could be filled promptly, not where prescriptions originate or whether patients can obtain timely appointments, telehealth assessment, or follow-up care. The persistence of geographic gaps alongside higher GP provision points to distribution constraints that prescribing rules alone do not resolve, including workforce density, pharmacy ordering practices, and referral pathways in low-volume settings.
